Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Free Cash Flow data on file, last reported at -$97.9 million in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 61.05% year-over-year to -$97.9 million in Q2 2026; TTM through May 2026 was -$296.8 million, a 37.42% decrease from a year earlier, with the FY2025 full-year figure at -$250.6 million, down 43.86% from the prior year.
• Free Cash Flow for Q2 2026 stood at -$97.9 million, down from -$73.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for NRIX reached as high as $31.9 million in Q4 2023 and fell as low as -$97.9 million in Q2 2026.
• Historically, Free Cash Flow has averaged -$47.2 million across 5 years, with a median of -$46.8 million in 2022.
• Across the five-year window, Free Cash Flow plunged 739.42% in 2022 and jumped 178.66% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$40.5 million in 2022, then soared by 178.66% to $31.9 million in 2023, then sank by 235.62% to -$43.2 million in 2024, then slumped by 54.76% to -$66.9 million in 2025, then slumped by 46.28% to -$97.9 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$97.9 million in Q2 2026, -$73.6 million in Q1 2026, and -$66.9 million in Q4 2025.